Antithrombotic therapy following transcatheter aortic valve intervention.
Sharma, Harish Afzal, Shazia Leick, Jürgen Werner, Nikos Doshi, Sagar N Nadir, M Adnan
Sharma, Harish
Afzal, Shazia
Leick, Jürgen
Werner, Nikos
Doshi, Sagar N
Nadir, M Adnan
Abstract
Transcatheter aortic valve replacement (TAVR) is increasingly being performed to treat symptomatic patients with aortic stenosis and annual procedure volume has overtaken surgical aortic valve replacement in the United States. However, current international guidelines were written prior to the publication of several important recent studies. Furthermore, European and American guidelines differ in their recommendations of antithrombotic therapy following TAVR. Consequently, there is a need to examine the literature to provide clinicians guidance on the optimum antithrombotic strategy, particularly as different patient populations exist. In this review, we examine the data for antiplatelet and anticoagulation therapy post-TAVR
MIDER Authors
Citations
Altmetric:
Date
2023-08-11
Type
Article
Subject
Cardiology
Collections
Citation
Sharma H, Afzal S, Leick J, Werner N, Doshi SN, Nadir MA. Antithrombotic therapy following transcatheter aortic valve intervention. Pharmacol Ther. 2023 Aug 11;250:108509. doi: 10.1016/j.pharmthera.2023.108509. Epub ahead of print. PMID: 37572882.
Journal / Source Title
Pharmacology & Therapeutics
DOI
10.1016/j.pharmthera.2023.108509
PMID
37572882
Publisher
Elsevier
Publisher’s URL
https://www.sciencedirect.com/science/article/abs/pii/S0163725823001730?via%3Dihub